DrugPatentWatch Database Preview

Details for Patent: 8,309,122

Which drugs does patent 8,309,122 protect, and when does it expire?

Patent 8,309,122 protects OPANA ER and is included in one NDA.

This patent has forty-seven patent family members in sixteen countries.

Summary for Patent: 8,309,122

Title:	Oxymorphone controlled release formulations
Abstract:	The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
Inventor(s):	Kao; Huai-Hung (Syosset, NY), Baichwal; Anand R. (Wappingers Falls, NY), McCall; Troy (Smyma, GA), Lee; David (Chadds Ford, PA)
Assignee:	Endo Pharmaceuticals Inc. (Chadds Ford, PA)
Application Number:	11/680,432
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,309,122
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form; Delivery; Use;

Drugs Protected by US Patent 8,309,122

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-001	Dec 9, 2011		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-002	Dec 9, 2011		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-003	Dec 9, 2011		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-004	Dec 9, 2011		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,309,122

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,276,250	Sustained release formulations of oxymorphone	➤ Sign Up
9,820,982	Oxymorphone controlled release formulations	➤ Sign Up
8,329,216	Oxymorphone controlled release formulations	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,309,122

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Poland	208484	➤ Sign Up
Poland	367277	➤ Sign Up
Poland	207748	➤ Sign Up
Poland	366430	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,309,122

For more information try a trial or see the plans and pricing